Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Janku

Showing results (111-120 of 277) with videos related to

Pageof 28
Sort By:
JCO Precision Oncology|July 21, 2022
Identification of <i>KRAS</i><sup></sup> Mutations in Circulating Tumor DNA in Patients With CancerKyaw Z Thein, Amadeo B Biter, Kimberly C Banks, et al.
The Oncologist|October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unitSiqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Cancer Medicine|October 10, 2024
Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant MelanomaJiri Polivka, Mohamed A Gouda, Mahyar Sharif, et al.
Cancer Research|October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsFilip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trialsMehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Investigational New Drugs|May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liverRabih Said, Razelle Kurzrock, Aung Naing, et al.
Breast Cancer Research : BCR|August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerNatalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer|January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancersJibran Ahmed, Filip Janku, Daniel D Karp, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Pageof 28

Showing results (111-120 of 277) with videos related to

Sort By:
Pageof 28
JCO Precision Oncology|July 21, 2022
Identification of <i>KRAS</i><sup></sup> Mutations in Circulating Tumor DNA in Patients With CancerKyaw Z Thein, Amadeo B Biter, Kimberly C Banks, et al.
The Oncologist|October 25, 2013
Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unitSiqing Fu, Lacey McQuinn, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2014
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analysesApostolia-Maria Tsimberidou, Sijin Wen, David S Hong, et al.
Cancer Medicine|October 10, 2024
Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early-Stage Malignant MelanomaJiri Polivka, Mohamed A Gouda, Mahyar Sharif, et al.
Cancer Research|October 16, 2012
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsFilip Janku, Jennifer J Wheler, Aung Naing, et al.
Cancer Chemotherapy and Pharmacology|June 12, 2016
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trialsMehmet Asim Bilen, Amy Patel, Kenneth R Hess, et al.
Investigational New Drugs|May 21, 2015
Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liverRabih Said, Razelle Kurzrock, Aung Naing, et al.
Breast Cancer Research : BCR|August 17, 2017
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancerNatalia Paez Arango, Erkan Yuca, Ming Zhao, et al.
Cancer|January 24, 2025
A phase 2 basket study of talabostat, a small-molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancersJibran Ahmed, Filip Janku, Daniel D Karp, et al.
Experimental Hematology & Oncology|April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trialVivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Pageof 28